Pfizer (PFE) AI Stock Analysis

• Market Cap: $129.99B
• Dividend Yield: 7.42%
• Average Volume (3M): 60.12M
• Price to Earnings (P/E): 16.2
• Beta (1Y): 0.27
• Revenue Growth: 8.77%
• EPS Growth: 272.80%
• Country: US
• Employees: 81,000
• Sector: Healthcare
• Sector Strength: 69
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.41
• Shares Outstanding: 5,671,454,600
• 10 Day Avg. Volume: 48,678,344
• 30 Day Avg. Volume: 60,122,727
• PEG Ratio: 0.06
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.34
• Price to Cash Flow (P/CF): 5.50
• P/FCF Ratio: 5.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $27.80
• Price Target Upside: 21.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17

Pfizer's overall stock score reflects its strong financial performance and strategic advancements in 2024, especially in the earnings call, which highlighted significant achievements. Valuation remains attractive with a high dividend yield. However, technical indicators suggest bearish momentum, and the lack of comprehensive financial data for 2024 warrants caution. The combination of these factors results in a moderately positive outlook for Pfizer's stock.

Positive Factors

Financial Performance

Pfizer's current P/E ratio and high dividend yield are expected to provide some support for the share price.

Market Growth

Ex-US markets could see growth with Eliquis and other vaccines, driven by continued share gains and strong launches.

Product Demand

Strong demand growth for US Eliquis is expected to offset pricing headwinds and previous quarter stocking issues.

Negative Factors

Dividend Concerns

Investors have concerns about the sustainability of Pfizer's nearly ~8% dividend yield, which is the industry's highest.

Product Discontinuation

Pfizer is discontinuing the drug Danuglipron due to a potential liver injury case, which is seen as a setback for the company's opportunity in obesity.

Regulatory Impact

The Medicare Part D redesign is anticipated to have an unfavorable impact on Pfizer.

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. is a leading global pharmaceutical corporation headquartered in New York City. It engages in the discovery, development, manufacture, and sale of healthcare products, with a focus on medicines and vaccines. Pfizer operates across multiple therapeutic areas, including oncology, immunology, cardiology, and neurology, and is known for its innovative research and development efforts, contributing to the advancement of healthcare worldwide.

How the Company Makes Money

Pfizer generates revenue through the sale of its pharmaceutical products and vaccines. The company's revenue model primarily involves the development and commercialization of prescription medicines, which are sold directly to healthcare providers, governments, and distributors. Key revenue streams include sales from established biopharmaceutical products, innovative medicines, and vaccines. Pfizer also engages in strategic collaborations and partnerships to enhance its clinical development and expand its market reach, contributing significantly to its earnings. Additionally, the company benefits from intellectual property rights, which protect its products from generic competition, allowing it to maintain pricing power and profitability.

Pfizer Financial Statement Overview

Summary

Pfizer's financial performance shows resilience with improved profitability metrics in 2024. The income statement reflects better operational efficiency, though revenue growth is slower than previous years. The balance sheet indicates a strong equity position, but missing 2024 data raises caution. Cash flow analysis is hindered by a lack of recent data, necessitating transparency for stability.

Income Statement

Pfizer has shown fluctuations in revenue with a significant decline from 2022 to 2023, followed by a recovery in 2024. Gross profit and net profit margins have improved in 2024, indicating better operational efficiency. The EBIT and EBITDA margins also show recovery, suggesting a return to profitability. However, the revenue growth rate from 2023 to 2024 is not as strong as previous years, indicating potential challenges in sustaining growth.

Balance Sheet

The balance sheet reveals a strong equity position with positive stockholders' equity. However, the absence of total assets and total debt figures for 2024 raises concerns. Historically, Pfizer has managed a reasonable debt-to-equity ratio, but high liabilities in previous years suggest a need for careful leverage management. The equity ratio implies a stable financial foundation, although the missing metrics in 2024 warrant caution.

Cash Flow

Pfizer's cash flow statement highlights a lack of data in 2024, raising concerns about cash generation capabilities. Previously, operating and free cash flows were positive, indicating strong cash flow management. The free cash flow to net income ratio has been healthy, but the missing 2024 data prevents a comprehensive assessment of current cash flow stability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
63.63B	58.50B	100.33B	81.29B	41.91B
	Gross Profit
47.21B	28.81B	65.99B	50.47B	33.22B
	EBIT
14.94B	3.36B	40.03B	24.83B	10.63B
	EBITDA
18.13B	9.56B	41.03B	30.79B	13.17B
	Net Income Common Stockholders
8.03B	2.12B	31.37B	21.98B	7.02B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.48B	12.69B	22.73B	31.07B	12.22B
	Total Assets
213.40B	226.50B	197.21B	181.48B	154.23B
	Total Debt
63.65B	70.84B	34.87B	37.00B	38.27B
	Net Debt
62.61B	67.99B	34.45B	35.05B	36.49B
	Total Liabilities
124.90B	137.21B	101.29B	104.01B	90.76B
	Stockholders Equity
88.20B	89.01B	95.66B	77.20B	63.24B
Cash Flow		Free Cash Flow
9.84B	4.79B	26.03B	29.87B	11.61B
	Operating Cash Flow
12.74B	8.70B	29.27B	32.58B	14.40B
	Investing Cash Flow
2.65B	-32.28B	-15.78B	-22.55B	-4.27B
	Financing Cash Flow
-17.14B	26.07B	-14.83B	-9.82B	-9.65B

Pfizer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Negative. The current price of 22.92 is below the 20-day moving average (MA) of 22.95, below the 50-day MA of 24.79, and below the 200-day MA of 26.55, indicating a bearish trend. The MACD of -0.72 indicates Negative momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 78.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFE.

Pfizer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JNJ	76 Outperform	$371.98B	26.66	29.45%	3.20%	-0.37%	29.21%
MRK	73 Outperform	$208.21B	11.62	40.81%	3.96%	4.26%	―
AZN	73 Outperform	$215.44B	30.65	17.60%	2.19%	18.03%	18.11%
PFE	68 Neutral	$129.99B	16.17	9.05%	7.42%	8.77%	272.80%
ABBV	63 Neutral	$329.14B	75.46	61.94%	3.49%	3.71%	-12.14%
AMGN	60 Neutral	$150.46B	37.02	67.55%	3.26%	18.64%	-39.39%
Sector *	51 Neutral	$5.32B	3.32	-40.25%	2.90%	17.93%	2.14%

Pfizer Corporate Events

Pfizer Projects Strong Financial Growth for 2025

Pfizer has announced its financial guidance for the full year 2025, projecting revenues between $61.0 and $64.0 billion, and adjusted diluted EPS between $2.80 and $3.00. The company expects operational growth in revenue and EPS, driven by cost savings and a strong product portfolio, despite challenges from the Inflation Reduction Act and generic competition.